CC
Commodore Capital Portfolio holdings
AUM
$1.42B
1-Year Return
73.3%
This Quarter Return
-12.94%
1 Year Return
+73.3%
3 Year Return
+1,330.82%
5 Year Return
–
10 Year Return
–
AUM
$1.36B
AUM Growth
-$7.47M
(-0.55%)
Cap. Flow
+$221M
Cap. Flow
% of AUM
16.26%
Top 10 Holdings %
Top 10 Hldgs %
65.02%
Holding
35
New
4
Increased
13
Reduced
4
Closed
4
Top Buys
| 1 |
Agios Pharmaceuticals
AGIO
|
$64M |
| 2 |
Celldex Therapeutics
CLDX
|
$58.1M |
| 3 |
Scholar Rock
SRRK
|
$25.6M |
| 4 |
Merus
MRUS
|
$25.2M |
| 5 |
Solid Biosciences
SLDB
|
$21.6M |
Top Sells
| 1 |
Soleno Therapeutics
SLNO
|
$26.8M |
| 2 |
Xenon Pharmaceuticals
XENE
|
$13.9M |
| 3 |
Alkermes
ALKS
|
$11.6M |
| 4 |
ABVX
Abivax
ABVX
|
$9.4M |
| 5 |
BBOT
BridgeBio Oncology Therapeutics, Inc. Common Stock
BBOT
|
$5.25M |
Sector Composition
| 1 | Healthcare | 99.43% |
| 2 | Financials | 0.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Neurogene
NGNE
$280M
| $10.8M | 0.8% |
925,000
+125,000
| +16% | +$1.46M |
|
27
Tyra Biosciences
TYRA
$650M
| $8.84M | 0.65% |
+950,000
| New | +$8.84M |
|
|
PCSC
28
Perceptive Capital Solutions Corp Class A Ordinary Shares
PCSC
$117M
| $7.73M | 0.57% |
750,000
| – | – |
|
29
Celcuity
CELC
$2.31B
| $7.03M | 0.52% |
695,650
+295,650
| +74% | +$2.99M |
|
30
VistaGen Therapeutics
VTGN
$112M
| $3.94M | 0.29% |
1,575,000
| – | – |
|
31
Avalo Therapeutics
AVTX
$138M
| $3.87M | 0.29% |
483,000
| – | – |
|
|
ABVX
32
Abivax
ABVX
$6.48B
| – | – |
-1,284,110
| Closed | -$9.4M |
|
33
Nkarta
NKTX
$151M
| – | – |
-351,848
| Closed | -$876K |
|
|
THRD
34
DELISTED
Third Harmonic Bio
THRD
| – | – |
-237,704
| Closed | -$2.45M |
|
|
BBOT
35
BridgeBio Oncology Therapeutics, Inc. Common Stock
BBOT
$790M
| – | – |
-500,000
| Closed | -$5.25M |
|